Ophthalmologists may soon have a new therapy at their disposal for treating inflammation and pain following cataract surgery.
Results from the Phase 3 OPTIMIZE-1 trial of OCS-01, a once-daily, preservative-free corticosteroid eye drop, were presented at the 2024 ASCRS Annual Meeting. Therapies that are currently available to patients recovering from cataract surgery involve multiple daily doses of different eye drops. If OCS-01 would gain FDA approval in the future, then the convenience of having a once daily eye drop would increase patient compliance as well as improve post-surgery outcomes.
The study results revealed that 57.2% of patients treated with OCS-01 had no inflammation as of Day 15 post-op and 75.5% of patients reported no ocular pain at Day 4. OCS-01 is highly concentrated with 15 times the concentration of available and approved dexamethasone eye drops as well as a better solubility profile to enable better eye tissue penetration.
The second Phase 3 trial is under way with results anticipated by the end of 2024.
